Guselkumab is a medication used in this trial to treat Crohn’s Disease. It works by targeting specific proteins in the immune system that are involved in inflammation. By blocking these proteins, guselkumab helps reduce inflammation in the gut, which can alleviate symptoms of Crohn’s Disease.

Golimumab is another medication used in the trial for Crohn’s Disease. It is an anti-inflammatory drug that targets a protein called tumor necrosis factor (TNF). By inhibiting TNF, golimumab helps decrease inflammation and can improve symptoms in patients with Crohn’s Disease.

JNJ-78934804 is an investigational therapy being studied in this trial. It is being tested to see how effective it is when used in combination with guselkumab and golimumab for treating Crohn’s Disease. The goal is to determine if this combination therapy can provide better results than using each medication alone.

Crohn’s Disease – Crohn’s Disease is a chronic inflammatory condition of the gastrointestinal tract, primarily affecting the small intestine and colon. It is characterized by periods of flare-ups and remission, where symptoms can vary in intensity. During active phases, individuals may experience abdominal pain, diarrhea, fatigue, and weight loss. The inflammation can penetrate deep into the layers of the bowel tissue, leading to complications such as strictures or fistulas. The exact cause of Crohn’s Disease is unknown, but it involves an abnormal immune response. The disease can affect any part of the digestive tract, from the mouth to the anus, but most commonly impacts the end of the small intestine.